Bristol Myers, Ono sue Amgen to block Opdivo biosimilar
Bristol Myers Squibb and Ono Pharmaceutical sued Amgen in Delaware federal court seeking to block Amgen’s proposed U.S. biosimilar of Opdivo.
Bristol Myers Squibb NYSE:BMY and Ono Pharmaceutical TSE:4528 have filed suit against Amgen NASDAQ:AMGN in Delaware federal court seeking to block Amgen's proposed U.S. biosimilar of their blockbuster cancer immunotherapy drug Opdivo. The case is Bristol-Myers Squibb Co. v.
Amgen Inc., U.S. Dist…